［1］ Lungberg A. Myalgia cruris epidemica［J］.Acta Paediatr，1957，46（1）：18-31.

［2］ Mitsionis GI，Manoudis GN，Lykissas MG，et al.Pyomyositis in children：early diagnosis and treatment［J］.J Pediatr Surg，2009，44（11）：2173-2178.

［3］ Bohan A，Peter JB.Polymyositis and dermatomyositis［J］.E Engl J Med，1975，292：344-347．

［4］ Hoogend IJ，Amato A，Lecky B，et a1.119th ENMC international workshop：trial design in adult idiopathic inflammatory myopathies，with exception of inclusion body myositis［J］.Neuromuscul Disord，2004，14（5）：337-345．

［5］ Brown VE，Pilkington CA，Feldman BM，et a1.An international consensus survey of the diagnostic criteria for juvenile dermatomyositis（JDM）［J］.Rheumatology（Oxford），2006，45（8）：990-993．

［6］ Crum-Cianflone NF.Infection and musculoskeletal conditions： infectious myositis［J］.Best Pract Res Clin Rheumatol，2006，20（6）：1083-1097.

［7］ Reed AM，Mason TG. Juvenile dermatomyositis［M］//Textbook of pediatric rheumatology.6th ed.Manson Publishing Ltd，2012：375-413.

［8］ Huber AM，Giannini EH，Bowyer SL，et a1.Protocols for the initial treatment of moderately severe juvenile dermatomyositis：results of a Children’s Arthritis and Rheumatology Research Alliance Consensus Conference［J］.Arthritis Care Res（Hoboken），2010，62（2）：219-225．

［9］ Seshadri R，Feldman BM，Ilowite N，et a1.The role of aggressive corticosteroid therapy in patients with juvenile dermatomyositis：a propensity score analysis［J］.Arthritis Rheum 2008，59：989-995．

［10］ Kim S，El-Hallak M，Dedeoglu F，et a1.Complete and sustained remission of juvenile dermatomyositis resulting from aggressive treatment［J］.Arthritis Rheum，2009，60：1825-1830．

［11］ Pons-Estel GJ，Salerni GE，Serrano RM，et al.Therapeutic plasma exchange for the management of refractory systemic autoimmune diseases：report of 31 cases and review of the literature［J］.Autoimmun Rev，201l，10（11）：679-684．

［12］ Wedderbun LR，Rider LG.Juvenile dermatomyositis：new developments in pathogenesis，assessment and treatment：best practice and research［J］.Clin Rheumatol，2009，23（5）：665-678．

［13］ Hasija R，Pistorio A，Ravelli A，et a1.Therapeutic approaches in the treatment of juvenile dermatomyositis in patients with recent-onset disease and in those experiencing disease flare：an international multicenter PRINTO study［J］.Arthritis Rheum，2011，63（10）：3142-3152．

［14］ Schiopu E，Philips K，Macdonald PM，et a1.Predictors of survival in a cohort of patients with polymyositis and dermatomyositis：effect of corticosteriods，methotrexate and azathioprine［J］.Arthritis Res Ther，2012，14（1）：22．

［15］ Yu KH， Wu YJ， Kuo CF， et al. Survival analysis of patients with dermatomyositis and polymyositis：analysis of 192 Chinese cases［J］.Clin Rheumatol，2011，30（12）：1595-1601．

［16］ Kotani T，Takeuchi T，Makino S，et al. Combination with corticosteroids and cyclosporin A improves pulmonary function test results and chest HRCT findings in dermatomyositis patients with acute/subacute interstitial pneumonia［J］.Clin Rheumatol，2011，30（8）：1021-1028．

［17］ Kotani T，Makino S，Takeuchj T，et al. Early intervention with corticosteroids and cyclosporin A and 2-h postdose blood concentration monitoring improves the prognosis of acute/subacute interstitial pneumonia in dermatomyositis［J］.J Rheumatol，2008，35（2）：254-259.

［18］ Ingegnoli F，Lubatti c，Ingegno1i A，et al. Interstitial lung disease outcomes by high resolution computed tomography（HRCT）in Anti-Jol antibody-positive polymyositis patients：a single centre study and review of the literature［J］.Autoimmun Rev，2012，11（5）：335-340．

［19］ Danieli MG，Calcabrini L，Calabrese V，et al. Intravenous immunoglobulin as add on treatment with mycophenolate mofetil in severe myositis［J］.Autoimmun Rev，2009，9（2）：124-127．

［20］ Morganroth PA，Kreider ME，Werth VP.Mycophenolate mofetil for interstitial lung disease in dermatomyositis［J］.Arthritis Care Res（Hoboken），2010，62（10）：1496-1501．

［21］ Saketkoo LA，Espinoza LR. Experience of mycophenolate mofetil in 10 patients with autoimmune-related interstitial lung disease demonstrates promising effects［J］.Am J Med Sci，2009，337：329-335．

［22］ Rouster-Stevens KA，Morgan GA，Wang D，et al. Mycophenolate mofetil：a possible therapeutic agent for children with juvenile dermatomyositis［J］.Arthritis Care Res （Hoboken），2010，62：1446-1451．

［23］ Ando M，Miyazaki E，Yamasue M，et al. Successful treatment with tacrolimus of progressive interstitial pneumonia associated with amyopathic dermatomyositis refractory to cyclosporine［J］.Clin Rheumatol.2010，29（4）：443-445．

［24］ Karnpylafka EI，Kosmidis ML，Panagiotakos DB，et al.The effect of intravenous immunoglobulin（ⅣIG）treatment on patients with dermatomyositis：a 4-year follow-up study［J］.Clin Exp Rheumatol，2012，30（3）：397-401．

［25］ Danieli MG，Pettinari L，Moretti R，et al. Subcutaneous immunoglobulin in polymyositis and dermatomyositis：a novel application［J］.Autoimmun Rev，2011，10（3）：144-149．

［26］ Riolo G，Towheed TE. Antitumor necrosis factor inhibitor therapy-induced dermatomyositis and fascitis［J］.J Rheumatol，2012，39（1）：192-194．

［27］ Oddis CV，Reed AM，Aggarwal R. Rituximab in the treatment of refractory adult and juvenile dermatomyositis（DM） and adult polymyositis（PM）：the RRIM study［J］．Arthritis Rheum，2013，65（2）：314-324．

［28］ Narzaki M，Hagihara K，Shima Y，et al. Therapeutic effect of tocilizumab on two patients with polymyositis［J］.Rheumatology，2011，50（7）：1344-1346．

［29］ Riley P，McCann LJ，Maillard SM，et al. Effectiveness of infliximab in the treatment of refractory juvenile dermatomyositis with Calcinosis［J］.Rheumatology，2008，47：877-880．

［30］ Miyamae T，Sano F，Ozawa R，et al. Efficacy of thalidomide in a girl with inflammatory calcinosis，a severe complication of juvenile dermatomyositis［J］.Pediatr Rheumatol Online J，2010，8：6．

［31］ Hashkes PJ，Wright BM，Lauer MS，et al. Mortality outcomes in pediatric rheumatology in the US［J］.Arthritis Rheum，2010，62（2）：599-608．

［32］ Martin N，Krol P，Smith S，et al. A national registry for juvenile dermatomyositis and other paediatric idiopathic inflammatory myopathies：10 years’experience；the Juvenile Dermatomyositis National（UK and Ireland）Cohort Biomarker Study and Repository for Idiopathic Inflammatory Myopathies［J］.Rheumatology（Oxford），2011，50（1）：137-145．

［33］ Na SJ，Kim SM，Sunwoo IN，et al. Clinical characteristics and outcomes of juvenile and adult dermatomyositis［J］.J Korean Med Sci，2009，24：715-721．

［34］ Ravelli A， Trail L， Ferrari C， et al. Long-term outcome and prognostic factors of juvenile dermatomyositis：a multinational，multicenter study of 490 patients［J］. Arthritis Care Res（Hoboken），2010，62：63-72．